

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 12.811

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2018 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorials

- 789** Greetings from the editor
J S Smolen
- 790** Chronic widespread pain and increased mortality: biopsychosocial interconnections
J A P Da Silva, R Geenen, J W G Jacobs
- 793** Tumour necrosis factor: out of my heart!
L Vereecke, D Elewaut

Views on news

- 795** Effects of immune checkpoint inhibitors on B cells: relationship to immune-related adverse events
D S Pisetsky

Recommendations

- 797** EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis
R Geenen, C L Overman, R Christensen, P Åsenlöf, S Capela, K L Huisinga, M E P Husebo, A J A Köke, Z Paskins, I A Pitsillidou, C Savel, J Austin, A L Hassett, G Severijns, M Stoffer-Marx, J W S Vlaeyen, C Fernández-de-las-Peñas, S J Ryan, S Bergman
- 808** 2018 update of the EULAR recommendations for the management of Behçet's syndrome
G Hatemi, R Christensen, D Bang, B Bodaghi, A F Celik, F Fortune, J Gaudric, A Gul, I Kötter, P Leccese, A Mahr, R Moots, Y Ozguler, J Richter, D Saadoun, C Salvarani, F Scuderi, P P Sfikakis, A Siva, M Stanford, I Tugal-Tutkun, R West, S Yurdakul, I Olivieri, H Yazici
- 819** Treating juvenile idiopathic arthritis to target: recommendations of an international task force
A Ravelli, A Consolaro, G Horneff, R M Laxer, D J Lovell, N M Wulffraat, J D Akeikusa, S M Al-Mayouf, J Antón, T Avčin, R A Berard, M W Beresford, R Burgos-Vargas, R Cimaz, F De Benedetti, E Demirkaya, D Foell, Y Itoh, P Lahdenne, E M Morgan, P Quartier, N Ruperto, R Russo, C Saad-Magalhães, S Sawhney, C Scott, S Shenoi, J F Swart, Y Uziel, S J Vastert, J S Smolen

Viewpoints

- 829** Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)
D van der Heijde, D I Daikh, N Betteridge, G R Burmester, A L Hassett, E L Matteson, R van Vollenhoven, S Lakhnpal
- 833** Designing effective graphs to get your message across
M Boers

Clinical and epidemiological research

- 840** Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease
C Gabay, B Fautrel, J Rech, F Spertini, E Feist, I Köter, E Hachulla, J Morel, T Schaeferbeke, M A Hamidou, T Martin, B Hellmich, P Lamprecht, H Schulze-Koops, D S Courvoisier, A Sleight, E J Schiffrin
- 848** Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register
J M Gwinnutt, D P M Symmons, A J MacGregor, J R Chipping, T Marshall, M Lunt, S M M Verstappen
- 855** Effect of pregnancy on disease flares in patients with systemic lupus erythematosus
A M Eudy, A M Siega-Riz, S M Engel, N Franceschini, A G Howard, M E B Clowse, M Petri
- 861** Are MRI-detected erosions specific for RA? A large explorative cross-sectional study
D M Boeters, W P Nieuwenhuis, H W van Steenberghe, M Reijnen, R B M Landewé, A H M van der Helm-van Mil
- 869** Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study
N W Tsao, E C Sayre, G Hanley, M Sadatsafavi, L D Lynd, C A Marra, M A De Vera

MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme.

See <http://authors.bmj.com/open-access/>

Member since 2008
JMS0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>

equator
network

recycle
When you have finished
with this please recycle it

- 875** Intramuscular glucocorticoid injection versus placebo injection in hip osteoarthritis: a 12-week blinded randomised controlled trial
D M J Dorleijn, P A J Luijsterburg, M Reijman, M Kloppenburg, J A N Verhaar, P J E Bindels, P K Bos, S M A Bierma-Zeinstra
- 883** Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
J T Merrill, W R Shanahan, M Scheinberg, K C Kalunian, D Wofsy, R S Martin
- 890** Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
P Mease, D van der Heijde, R Landewé, S Mpofo, P Rahman, H Tahir, A Singhal, E Boettcher, S Navarra, K Meiser, A Readie, L Pricop, K Abrams
- 898** Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
J K Park, Y J Lee, K Shin, Y-J Ha, E Y Lee, Y W Song, Y Choi, K L Winthrop, E B Lee
- 905** Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
A I Rutherford, S Subesinghe, K L Hyrich, J B Galloway
- 911** Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE
D S Pisetsky, D M Spencer, P E Lipsky, B H Rovin
- 914** Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
S B Cohen, A Alonso-Ruiz, P A Klimiuk, E C Lee, N Peter, I Sonderegger, D Assudani
- 922** 'Deep Koebner' phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis
I Tinazzi, D McGonagle, S Z Aydin, D Chessa, A Marchetta, P Macchioni

Basic and translational research

- 926** Comorbid TNF-mediated heart valve disease and chronic polyarthritis share common mesenchymal cell-mediated aetiopathogenesis
L Ntari, M Sakkou, P Chouvardas, I Mourouzis, A Prados, M C Denis, N Karagianni, C Pantos, G Kollias
- 935** Tyrosine kinase Fyn promotes osteoarthritis by activating the β -catenin pathway
K Li, Y Zhang, Y Zhang, W Jiang, J Shen, S Xu, D Cai, J Shen, B Huang, M Li, Q Song, Y Jiang, A Liu, X Bai
- 944** Differential ubiquitination in NETs regulates macrophage responses in systemic lupus erythematosus
A Barrera-Vargas, D Gómez-Martín, C Carmona-Rivera, J Merayo-Chalico, J Torres-Ruiz, Z Manna, S Hasni, J Alcocer-Varela, M J Kaplan

Letters

- 952** Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis
G Emmi, G M Rossi, M L Urban, E Silvestri, D Prisco, M Goldoni, A Vaglio
- 954** Antibodies against collagen type II are not a general marker of acute arthritis onset
V A Manivel, D van der Woude, R Toes, A Filer, K Raza, J Rönnelid
- 955** B-cell receptor sequencing of anti-citrullinated protein antibody (ACPA) IgG-expressing B cells indicates a selective advantage for the introduction of N-glycosylation sites during somatic hypermutation
R D Vergoesen, L M Slot, L Hafkenscheid, M T Koning, E I H van der Voort, C A Grooff, G Zervakis, H Veelken, T W J Huizinga, T Rispen, H U Scherer, R E M Toes
- 958** Dual-energy CT: a new imaging modality for bone marrow oedema in rheumatoid arthritis
L Jans, I De Kock, N Herregods, K Verstraete, F Van den Bosch, P Carron, E H Oei, D Elewaut, P Jacques

Corrections

- 950** Correction: *Cross-phenotype analysis of ImmunoChip data identifies KDM4C as a relevant locus for the development of systemic vasculitis*
- 960** Correction: *Stratification of knee osteoarthritis: two major patient subgroups identified by genome-wide expression analysis of articular cartilage*

- 960** Correction: *EULAR/PreS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases*

Electronic pages

- e27** Chondroitin sulfate for knee osteoarthritis
D M Marcus
- e28** Some concerns and improvements from Turkey
O E Cinar, A Erden, A Sari, B Armagan, L Kilic
- e29** Duration of maintenance therapy for ANCA-associated vasculitis: more questions than answers
P I Novikov, I Smitienko, S V Moiseev
- e30** Challenging judgement of a low-positive ACPA test in the context of individuals at risk of RA
A H Hensvold, A I Catrina
- e31** The challenge to interpret conflicting results and the need of a univocal definition for germinal centres in primary Sjögren's syndrome
A Alunno, F Carubbi, R Giacomelli, R Gerli
- e32** Standardisation of the detection of germinal centres in salivary gland biopsies of patients with primary Sjögren's syndrome is needed to assess their clinical relevance
E A Haacke, B van der Vegt, A Vissink, F K L Spijkeervet, H Bootsma, F G M Kroese
- e33** Large joint involvement at first presentation with RA, an unfavourable feature: results of a large longitudinal study with functioning and DMARD-free sustained remission as outcomes
L E Burgers, D M Boeters, A H M van der Helm-van Mil
- e34** Alternative diagnoses in patients with chronic back pain not diagnosed with axial spondyloarthritis: data from the SPACE cohort
Z Ez-Zaitouni, R B M Landewé, D van der Heijde, F A van Gaalen